SI1553938T1 - Uporaba epotilonskih derivatov za zdravljenje hiperparatiroidizma - Google Patents

Uporaba epotilonskih derivatov za zdravljenje hiperparatiroidizma

Info

Publication number
SI1553938T1
SI1553938T1 SI200330741T SI200330741T SI1553938T1 SI 1553938 T1 SI1553938 T1 SI 1553938T1 SI 200330741 T SI200330741 T SI 200330741T SI 200330741 T SI200330741 T SI 200330741T SI 1553938 T1 SI1553938 T1 SI 1553938T1
Authority
SI
Slovenia
Prior art keywords
hyperparathyroidism
treatment
epothilone derivatives
animal
epothilone
Prior art date
Application number
SI200330741T
Other languages
English (en)
Slovenian (sl)
Inventor
Eugene A Woltering
Original Assignee
Univ Louisiana State
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Louisiana State filed Critical Univ Louisiana State
Publication of SI1553938T1 publication Critical patent/SI1553938T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A61P5/20—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
SI200330741T 2002-10-15 2003-10-13 Uporaba epotilonskih derivatov za zdravljenje hiperparatiroidizma SI1553938T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41859202P 2002-10-15 2002-10-15
PCT/IB2003/004514 WO2004035050A1 (en) 2002-10-15 2003-10-13 Use of epothilone derivatives for the treatment of hyperparathyroidism
EP03748446A EP1553938B1 (en) 2002-10-15 2003-10-13 Use of epothilone derivatives for the treatment of hyperparathyroidism

Publications (1)

Publication Number Publication Date
SI1553938T1 true SI1553938T1 (sl) 2007-06-30

Family

ID=32107949

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200330741T SI1553938T1 (sl) 2002-10-15 2003-10-13 Uporaba epotilonskih derivatov za zdravljenje hiperparatiroidizma

Country Status (15)

Country Link
US (2) US20060142354A1 (cg-RX-API-DMAC10.html)
EP (1) EP1553938B1 (cg-RX-API-DMAC10.html)
JP (1) JP4672368B2 (cg-RX-API-DMAC10.html)
CN (1) CN1297269C (cg-RX-API-DMAC10.html)
AT (1) ATE350034T1 (cg-RX-API-DMAC10.html)
AU (1) AU2003267751A1 (cg-RX-API-DMAC10.html)
BR (1) BR0315293A (cg-RX-API-DMAC10.html)
CA (1) CA2501717C (cg-RX-API-DMAC10.html)
CY (1) CY1106385T1 (cg-RX-API-DMAC10.html)
DE (1) DE60310975T2 (cg-RX-API-DMAC10.html)
DK (1) DK1553938T3 (cg-RX-API-DMAC10.html)
ES (1) ES2279139T3 (cg-RX-API-DMAC10.html)
PT (1) PT1553938E (cg-RX-API-DMAC10.html)
SI (1) SI1553938T1 (cg-RX-API-DMAC10.html)
WO (1) WO2004035050A1 (cg-RX-API-DMAC10.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE350383T1 (de) 2002-08-23 2007-01-15 Sloan Kettering Inst Cancer Synthese von epothilonen, zwischenprodukte dafür, analoga und deren verwendungen
US6921769B2 (en) 2002-08-23 2005-07-26 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US7649006B2 (en) 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69403966T3 (de) * 1993-07-19 2008-04-17 Angiotech Pharmaceuticals, Inc., Vancouver Anti-angiogene mittel und verfahren zu deren verwendung
ATE267197T1 (de) * 1996-11-18 2004-06-15 Biotechnolog Forschung Gmbh Epothilon d, dessen herstellung und dessen verwendung als cytostatisches mittel bzw. als pflanzenschutzmittel
US6380394B1 (en) * 1996-12-13 2002-04-30 The Scripps Research Institute Epothilone analogs
KR20080016756A (ko) * 1998-02-05 2008-02-21 노파르티스 아게 유기화합물 함유 조성물
US6302838B1 (en) * 1998-02-25 2001-10-16 Novartis Ag Cancer treatment with epothilones

Also Published As

Publication number Publication date
DE60310975D1 (de) 2007-02-15
JP2006504751A (ja) 2006-02-09
JP4672368B2 (ja) 2011-04-20
BR0315293A (pt) 2005-08-30
US20060142354A1 (en) 2006-06-29
WO2004035050A1 (en) 2004-04-29
CY1106385T1 (el) 2011-10-12
CN1297269C (zh) 2007-01-31
US20110152329A1 (en) 2011-06-23
ATE350034T1 (de) 2007-01-15
PT1553938E (pt) 2007-03-30
EP1553938A1 (en) 2005-07-20
DK1553938T3 (da) 2007-03-26
EP1553938B1 (en) 2007-01-03
ES2279139T3 (es) 2007-08-16
AU2003267751A1 (en) 2004-05-04
CN1703217A (zh) 2005-11-30
CA2501717A1 (en) 2004-04-29
HK1080768A1 (en) 2006-05-04
DE60310975T2 (de) 2007-07-12
CA2501717C (en) 2012-09-18

Similar Documents

Publication Publication Date Title
DE60329001D1 (en) 8-hydroxychinolinderivate
PL1940786T3 (pl) Pochodne bifenylowe i ich zastosowanie w leczeniu zapalenia wątroby typu C
MY138352A (en) Benzothiazole derivatives
AU5584901A (en) Use of cyclic gmp-specific phosphodiesterase inhibitors for treatment of parkinson's disease
GB0225475D0 (en) Therapeutic agents
DE50311898D1 (de) Fredericamycin-derivate als arzneimittel zur tumorbehandlung
GEP20084551B (en) 4-phenylamino-quinazolin-6-yl-amides
GB0318447D0 (en) Therapeutic agents
TNSN04203A1 (en) Benzoxazinone-derived compounds, their preparation and use as medicaments
TW200420549A (en) Thiazole derivatives
GB0112348D0 (en) Compounds
PT1696905E (pt) 2-aminotetralinas substituídas para o tratamento preventivo da doença de parkinson
BR0316458A (pt) Composto, composição farmacêutica, método de tratamento ou prevenção de doenças, método para intensificar a cognição em um paciente saudável, e, uso de um composto
BR0316723A (pt) Derivados de anilinopirazol úteis para o tratamento de diabetes
WO2006081431A3 (en) Compounds for treating inflammatory and demyelinating diseases
WO2004014906A3 (en) Nitro and amino substituted dibenzonaphthyridines as topoisomerase agents
AU2003267751A1 (en) Use of epothilone derivatives for the treatment of hyperparathyroidism
IL156140A0 (en) Use of substituted 6-dimethylaminomethyl-1-phenyl-cyclohexane compounds for treating urinary incontinence
PT1183046E (pt) Derivado de aminotetralina para a terapia de doencas cardiovasculares
WO2007047893A3 (en) Use of dasatinib for the treatment of bone metastasis
HK1080369A1 (zh) 用於治疗多发性骨髓瘤的埃博霉素衍生物
TW200730177A (en) 4 anilino-3-quinolinecarbonitriles for the treatment of cancer
AU2003216965A1 (en) Compounds, particularly of urea derivatives or ester derivatives of haloacetamidobenzoic acid and use thereof for the treatment of parasitic diseases
DE602005015323D1 (de) Prostaglandinanaloga
PL374696A1 (en) Use of 4-pyridylmethyl-phthalazine derivatives for the manufacture of a medicament for the treatment of myelodysplastic syndromes